Indian HealthTech's Journey to Australian TGA Approval

Executive Summary

HealthTech is one of the most highly regulated sectors in Australia. "MediVital India" (anonymized), a Bengaluru-based startup, developed a revolutionary IoT-based cardiac monitoring patch. While they had thousands of users in India, entering the Australian market required more than just a business registration. They had to satisfy the Therapeutic Goods Administration (TGA) and comply with the strict Australian Privacy Principles (APPs).

CorpArray was engaged to manage the Australian corporate setup and provide strategic regulatory advisory. This case study details how we helped MediVital secure TGA registration and architect a compliant data residency framework, leading to a successful pilot with a major private hospital in New South Wales.

The Challenge: A High Regulatory Bar

The Australian healthcare market offers high margins but demands world-class quality and privacy standards. MediVital faced three significant roadblocks:

1. TGA Class IIa Classification

As a cardiac monitor, the patch was classified as a Class IIa Medical Device. This required the Indian manufacturer to have ISO 13485 certification and a comprehensive technical file that met Australian standards. Without TGA approval, selling the device in Australia is a criminal offense.

2. Australian Privacy Principles (APP)

Health data is considered "Sensitive Information" under the Australian Privacy Act 1988. Unlike general data, health data must be handled with extreme care, especially concerning cross-border disclosure. MediVital’s existing cloud architecture in India was not compliant with APP 8.

3. The Sponsor Requirement

Foreign manufacturers must appoint an Australian Sponsor who acts as the legal representative to the TGA. The Sponsor carries significant legal liability for the safety and efficacy of the device.

The CorpArray Strategy: A Phased Regulatory Entry

We advised MediVital to avoid a 'direct launch' and instead follow a phased compliance path.

Step 1: Entity Structuring & Sponsorship

We incorporated "MediVital Australia Pty Ltd" and established its office in Sydney. To meet the TGA Sponsor requirement, we provided a Nominee Director with a background in healthcare compliance, ensuring the company had a 'Fit and Proper' local representative.

Step 2: TGA Technical File Gap Analysis

We worked with MediVital’s engineering team in Bengaluru to perform a gap analysis of their existing documentation. We ensured their 'Quality Management System' (QMS) was updated to include Australian 'Post-Market Monitoring' requirements, which are often stricter than those in India.

Step 3: Data Residency & "My Health Record" Preparedness

We advised the client to move all Australian patient data to an Australian-based cloud region (AWS Sydney). We drafted a 'Privacy Impact Assessment' (PIA) and updated their Privacy Policy to be explicitly compliant with the 13 APPs. We also ensured the system was architected to potentially integrate with Australia's 'My Health Record' system in the future.

How the Problem Was Solved: Execution

• ISO 13485 Alignment: We helped the Indian team align their manufacturing processes with the specific requirements of the TGA's audit framework.
• FEMA/ODI Reporting: We ensured the $500,000 AUD initial investment from India was correctly reported as an 'Overseas Investment' to the RBI, ensuring the company could eventually repatriate profits from Australia.
• ABN/GST & Insurance: We secured a specialized medical liability insurance policy for the Australian entity, which was a prerequisite for the hospital pilot.

Benefits and Outcomes

• TGA Approval Granted: The device was successfully listed on the Australian Register of Therapeutic Goods (ARTG) within 7 months.
• Hospital Pilot Secured: MediVital signed a pilot agreement with a leading Sydney hospital to monitor 500 post-surgery patients.
• Zero Privacy Breaches: The robust data residency model ensured 100% compliance during a third-party cybersecurity audit.
• Market Value Increase: The TGA approval significantly increased the company's valuation for its Series C funding round in India.